Skip to main content
TARS
NASDAQ Life Sciences

XDEMVY Sales Jump 64% to $194.6M, but $632M IPR&D Charge Drives $668M Quarterly Loss

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$71.24
Mkt Cap
$3.581B
52W Low
$53.89
52W High
$91.53
52W Position info
32% above low
Off High info
22% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

TARS sits 32% above its 52-week low of $53.89.

Summary

XDEMVY net product sales hit $194.6 million in Q3 2026, up roughly 64% from $118.7 million a year earlier, with gross margins steady near 93%. The top line keeps compounding off the Q2 print of $173.9 million, and management noted prescribing eye care professionals rose about 20% through the quarter while refills reached roughly 20% of prescriptions. The reported net loss of $668.3 million, or $14.40 per share, is almost entirely accounting: $632.2 million of acquired IPR&D expense from the iRenix ($81.0 million) and Alkeus ($551.2 million) deals, which were expensed because the programs have no alternative future use. Cash and marketable securities stood at $309.6 million at quarter-end, and the company also named Neera Clase Chief Commercial Officer. The real question for the stock is whether the underlying commercial trend holds into year-end; the pipeline readouts that matter are TP-04 Kore and TP-05 Calliope topline data, both expected in the first half of 2027.

At the time of this announcement, TARS was trading at $71.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $53.89 to $91.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $78.00 info
Change: +$4.00 (+5%) info
Market Cap: $3.83B info
TARS
Oct 13, 2026, 4:00 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $70.82
Real-time Price: $78.00 info
Change: +$7.18 (+10%) info
Market Cap: $3.83B info
TARS
Sep 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.12
Real-time Price: $78.00 info
Change: -$3.12 (-4%) info
Market Cap: $3.83B info
TARS
Aug 06, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $58.27
Real-time Price: $78.00 info
Change: +$19.73 (+34%) info
Market Cap: $3.83B info
TARS
Aug 06, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $58.27
Real-time Price: $78.00 info
Change: +$19.73 (+34%) info
Market Cap: $3.83B info